A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study
<p>Abstract</p> <p>Background</p> <p>Cancer cachexia is a syndrome of progressive weight loss. Non-small cell lung cancer patients experience a high incidence of cachexia of 61%. Research into methods to combat cancer cachexia in various tumour sites has recently progre...
Main Authors: | Rogers Elaine S, MacLeod Roderick D, Stewart Joanna, Bird Stephen P, Keogh Justin WL |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-11-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/11/493 |
Similar Items
-
CELEBREX: THE FIRST SPECIFIC INHIBITOR OF COX-2: NEW DATA
by: E L Nassonov
Published: (2000-08-01) -
CELEBREX-A SPECIFIC INHIBITOR OF CYCLOOXIGENASE-2: EFFICACY AND TOLERABILITY
by: - -
Published: (2000-04-01) -
CELEBREX IN TREATMENT OF VERTEBRAL PAIN SYNDROME IN SYSTEMICV LUPUS ERYTHEMATOSUS
by: N. P. Shilkina, et al.
Published: (2002-06-01) -
CELEBREX IN TREATMENT OF VERTEBRAL PAIN SYNDROME IN SYSTEMICV LUPUS ERYTHEMATOSUS
by: N. P. Shilkina
Published: (2002-06-01) -
Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study
by: Wenxin Hong, et al.
Published: (2020-11-01)